

# European Partnership for Personalised Medicine calling for national and regional involvement

An information event by ICPerMed and ERA PerMed

May 31, 2021




# Presentation of EP PerMed

Monika Frenzel, ANR, France

(Member of ICPeMed/ERA PerMed Preparatory Group)

# ICPerMeds and ERA PerMeds input for the future European Partnership for Personalised Medicine



## Preparatory group and draft concept paper:

Upon request from EC, a preparatory group (4 seats ICPerMed + 4 seats ERA PerMed + European Commission, EC) was set up to develop a draft concept paper as input for the European Partnership for Personalised Medicine, **EP PerMed**.

ICPerMed/ERA PerMed set-up each one internal support group for additional input.



# Draft concept paper for the EP PerMed

- Objective of document:
  - To provide inspiration for the EU Member States Group, which eventually will decide on the scope and format of the new partnership program,
  - To promote the European Partnership for Personalised Medicine in national and regional contexts by ICPeMed, ERA PerMed members and associated partner organisation, the ICPeMed family and others.
- Published on 18 February 2021:
  - ERA PerMed: <https://erapermed.isciii.es/draft-concept-paper-european-partnership-for-personalised-medicine-ep-permed/>
  - ICPeMed: <https://www.icpermed.eu/en/draft-concept-paper-european-partnership-for-personalised-medicine-777.php>

## Draft concept paper for the EP PerMed

### **Building on experiences from ERA PerMed and ICPerMed.**

This document was jointly developed and approved by the ICPerMed and ERA PerMed consortia as input and supporting document for the Member States consultation on the future European Partnership in Personalised Medicine organised by the EC.

The document received valuable EC input but does not represent an official document developed and approved by the EC.

The document is not the official partnership proposal.

# European Partnership for Personalised Medicine (EP PerMed)

- Structure of the document based on EC template (with modifications)
- Content:
  1. General information – Summary
  2. Context and necessity for joint collaborations in personalised medicine
  3. General overview of the personalised medicine environment
  4. EP PerMed: Common vision, objectives, expected impacts and synergies
  5. EP PerMed composition and target group
  6. Planned Implementation (activities, resources, governance, stakeholders)

## **Personalised Medicine: A major opportunity for society to provide benefits to patients and citizens and health systems**

Key questions that Personalised Medicine (PM) tackles are:

- Why does a treatment for a certain disease work very well for one patient, but poorly or not at all for another patient?
- What is the benefit of individual molecular, clinical or lifestyle data for the development of personalised prevention, diagnostics, and treatment?
- How can the knowledge of an individual genetic profile or personal setting help to avoid health risks and support a healthy life?
- Can the use of PM be cost effective?


**Personalised Medicine: A major opportunity for society to provide benefits to patients and citizens and health systems**

**Personalised Medicine is a principal driver towards optimised healthcare, due to its great potential for disease prevention, diagnostic and treatment.**

How to prepare Europe with its heterogeneous regional and national healthcare systems for this improvement?



## Increasing commitment for and investment in PM



EC supporting joint efforts and activities related to PM to establishing Europe as a global leader in the field

## Increasing commitment for and investment in PM



- PERSEPHONE project
- MASTER – Innovation Driver for Personalised Oncology
- Electronic medical records (EMR) for personalised treatment

- 2025 France Genomic Medicine Initiative
- Genomic Medicine Sweden
- Pharmacogenetic Recommendations for PM
- Navarra 1,000 Genomes Project
- Network Genomic Medicine (NGM) Lung Cancer

Increased efforts in the PM field for PM research and implementation on regional and national level but also in collaborations across countries


## Increasing commitment for and investment in PM



### ICPerMed Family

#### Personalised Medicine in the RIS3 priorities

51 RIS3 out of the 145 analysed, explicitly prioritise Personalised Medicine (35%)




ICPerMed: connects today more than 40 partners (30 countries) with a common goal of aligning and supporting efforts on PM research and implementation.

ERA PerMed: largest ERA-Net in the health sector, 32 partners from 23 countries and 5 regions. Around 100 million Euros expected to be invested in PM research by 2022.


Seven CSAs: ICPerMed Secretariat, health economics, clinical trial design, international collaboration and regional perspective.

51 out of 145 (34%) Research and Innovation Smart Specialisation Strategy explicitly prioritise PM.


# General overview of the PM environment



# Necessity for a European Partnership




# Necessity for a European Partnership



**EP PerMed:** enable implementation of **PM approaches for the benefit of citizen and patients** by

- Fostering cooperation among the relevant stakeholders and investment in R&I,
- Transversal activities promoting the development along the four crucial axes.

# Why to participate in EP PerMed?



**None of the current and future challenges for PM can be solved by any one player alone. All key players in the field need to work together across borders in order to solve the problems and progress in delivering PM to the citizen.**


## Establish EP PerMed to:

- bridge the gap between PM research and its implementation in healthcare systems.
- bring together all the stakeholders involved in this field in the partnership.

# Common vision, objectives, expected impacts

The vision of EP PerMed is full implementation of PM in healthcare to the benefit of patients, citizens and the society.

## EP PerMed



5 Key elements of the EP PerMed structure



# EP PerMed objectives

- Increase PM-related multidisciplinary research and innovation throughout the entire value chain
- Promote translation of basic PM research results into clinical practice
- Promote uptake of PM innovation by the market and ensure patient benefit
- Track and communicate on successful implementation of PM in healthcare systems



PM Implementation

OPERATIONAL

- Development and implementation of funding strategies
- Development of Strategic Papers, Guidelines & Policy Papers
- Development of Education and Literacy in PM
- Create Synergies: Collaboration, dissemination and networking activities
- Improve knowledge base: Research, Analyses and Mapping

Operational objectives: assist EP PerMed to develop the overall objectives.  
Both types of proposed objectives: help to drive the field towards PM implementation.

# EP PerMed expected impact

**EP PerMed  
Overall  
Impact:  
Enabling  
Personalised  
Medicine for  
the Citizen**

**Development  
Axis 1: Basic &  
Translational  
Science**

**Main Impact:  
Europe at the  
forefront of R&I  
towards better  
evidence for PM  
for diagnosis,  
treatment and  
prevention**

**Development  
Axis 2: Policy  
Development**

**Main Impact:  
Harmonised  
implementation  
of PM in  
healthcare  
systems across  
Europe**

**Development  
Axis 3:  
Regulation &  
Market Access**


**Main Impact:  
Facilitated  
uptake of PM  
innovation by  
health systems**

**Development  
Axis 4: Citizen  
& patient  
empowerment**

**Main Impact: A  
common  
language and  
understanding  
on PM for  
citizens,  
patients and  
health  
professionals**

# Planned Implementation

Potential structure of the EP PerMed under the general goal: “PM Implementation”.




**Coordination of different kinds of joint funding actions, comprising e.g.:**

- Transnational, multidisciplinary research funding – ERA-Net like calls;
- Networking calls;
- Research Innovation and Technology Calls (RITC) – towards start-ups and market access.


# Planned Implementation

Potential structure of the EP PerMed under the general goal: “PM Implementation”.




# Planned Implementation

Potential structure of the EP PerMed under the general goal: “PM Implementation”.




# Planned Implementation

Potential structure of the EP PerMed under the general goal: “PM Implementation”.



# Planned Implementation

Potential structure of the EP PerMed under the general goal: “PM Implementation”.




The pillars are interconnected.

## Goal:

- Participation of **all European countries** and international organisations.
- Making **EP PerMed a global leader in the PM** field.

# Planned Implementation

Potential structure of the EP PerMed under the general goal: “PM Implementation”.



The pillars are interconnected.

EP PerMed members (beneficiaries)

EP PerMed partners

## EP PerMed members (beneficiaries):

Health and R&I ministries, regional authorities, regional and national research funding agencies (R&I and technology funding agencies) and foundations


## EP PerMed partners:

Public and private ‘not-for-profit’ health research funding and policy organisations, payers and healthcare institutions




# Planned Implementation

Potential structure of the EP PerMed under the general goal: “PM Implementation”.



**Stakeholders:** The list of stakeholders is not exhaustive and might be adapted in the course of the partnership and for the respective activities.

# EP PerMed governance




EP PerMed will...

- Develop **well-defined annual work plans**.
- **Act in a dynamic way and adjust its focus areas**.
- Be **flexible and adapt the focus on the key bottlenecks** that might change over time.

# Interaction with stakeholders / synergies

Interactions with a number of important stakeholders outside EP PerMed are absolutely critical, in order to achieve the overall objectives of EP PerMed.




**Stakeholders**

**Co-funded European Partnerships  
and other Health Programmes and initiatives**

# Framework - summary

## Research and Innovation towards PM Implementation in Healthcare



## EP PerMed will be a prime driver for developing and implementing PM

- By establishing priorities for research funding,
- By aligning PM strategies,
- By developing educational and literacy strategies,
- By supporting policy development.

The ICPeMed/ERA PeMed preparatory group is happy to provide further support regarding the EP PeMed documents

Please send questions to:

- [ICPerMed@dlr.de](mailto:ICPerMed@dlr.de)
- [ERAPerMed@agencerecherche.fr](mailto:ERAPerMed@agencerecherche.fr)